AI-guided treatment choices for advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study develops and validates a multimodal artificial intelligence model that combines digital pathology and MRI radiomics to predict treatment response in advanced hepatocellular carcinoma. The model uses RECIST 1.1 as the primary benchmark for assessing responses to systemic therapies. The study leverages archival tissue and imaging data, aiming to identify patients most likely to benefit from current systemic options. Participating sites include several major hospitals in Belgium, with data collected under informed consent for secondary use. No interventional treatment is described within the protocol itself; the focus is on predictive modeling and validation.

Why it matters

Who can join: the full rules

Participants eligible for inclusion in this Study must meet all of the following criteria:

* Male or female, age \> 18 years
* Hepatocellular carcinoma treated with systemic treatment during the disease course
* Histological confirmation of HCC within one year of the start of systemic treatment OR the availability of an MRI of the liver within 6 months of the start of systemic treatment
* Left-over tissue from previous diagnostic biopsy available
* Ability to sign informed consent for secondary use of archival tissue and data collection for study-specific research for patients who are alive and that have not yet reached a 5-year follow-up period.

Participants eligible for this Study must not meet any of the following criteria:

* Hepatocellular carcinoma not treated systemically
* Other malignancies of the liver, including cholangiocarcinoma

Where it's running

• Hôpital Universitaire de Bruxelles
  Anderlecht, Belgium Recruiting
• Imelda Ziekenhuis
  Bonheiden, Belgium Recruiting
• AZ Sint-Lucas Brugge
  Bruges, Belgium Recruiting
• Universitair Ziekenhuis Antwerpen
  Edegem, Belgium Recruiting
• UZ Leuven
  Leuven, Belgium Recruiting

Study contacts

• Study coordinator: Jeroen Dekervel, MD PhD
• Email: jeroen.dekervel@uzleuven.be
• Phone: +3216344225

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• DNP-MRSI to predict HCC treatment response

  This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07807475

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.